FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2026/02/103867 [Registered on: 13/02/2026] Trial Registered Prospectively
Last Modified On: 07/02/2026
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Drug 
Study Design  Other 
Public Title of Study   Use of Intravenous Tenecteplase in Participants with Acute Ischemic Stroke 
Scientific Title of Study   A Multicentre, Prospective, Randomized, Open Label, Blinded-endpoint Trial to Optimize the Use of Intravenous Tenecteplase in Participants with Acute Ischemic Stroke (ACT-WHEN) 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NCT06320431  ClinicalTrials.gov 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr P N Sylaja  
Designation  Professor of Neurology  
Affiliation  Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum  
Address  Comprehensive Stroke Care Program, Room No: 3109, Stroke Office, Department of Neurology, Medical College P.O

Thiruvananthapuram
KERALA
695011
India 
Phone  04712524482  
Fax    
Email  sylajapn@hotmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Jeyaraj Durai Pandian  
Designation  Principal and Professor  
Affiliation  Christian Medical College and Hospital, Ludhiana  
Address  Department of Neurology, Christian Medical College and Hospital, Brown Road, Ludhiana

Ludhiana
PUNJAB
141008
India 
Phone  9915784750  
Fax    
Email  jeyarajpandian@hotmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr P N Sylaja  
Designation  Professor of Neurology  
Affiliation  Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum  
Address  Comprehensive Stroke Care Program, Room No: 3109, Stroke Office, Department of Neurology, Medical College P.O

Thiruvananthapuram
KERALA
695011
India 
Phone  04712524482  
Fax    
Email  sylajapn@hotmail.com  
 
Source of Monetary or Material Support  
University of Calgary, Foothills Medical Centre 1403 29th Street NW Calgary, Alberta, Canada T2N 2T9 
 
Primary Sponsor  
Name  University of Calgary 
Address  Foothills Medical Centre 1403 29th Street NW Calgary, Alberta, Canada T2N 2T9 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     Australia
Canada
China
India  
Sites of Study  
No of Sites = 28  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Sanjeev Kumar Bhoi   All India Institute of Medical Sciences, Bhubaneswar   Department of neurology, All India Institute of Medical Sciences, Sijua, Patrapada, Bhubaneswar - 751019
Khordha
ORISSA 
9919787978

neuro_sanjeev@aiimsbhubaneswar.edu.in 
Dr Ashish Sharma  All India Institute of Medical Sciences, Bilaspur  Department of Neurology, All India Institute of Medical Sciences, Bilaspur -174037
Bilaspur
HIMACHAL PRADESH 
9816397700

ashishsharmamd@yahoo.co.in 
Dr Mritunjai Singh   All India Institute of Medical Sciences, Rishikesh   Department of Neurology, All India Institute of Medical Sciences, Shivaji Nagar, Rishikesh - 249203
Dehradun
UTTARANCHAL 
9997010096

mritunjasingh@gmail.com  
Dr Vivek K Nambiar  Amrita Institute of Medical Sciences and Research Centre, Kochi   Department of Stroke Medicine, G block, Ground floor, Ponekkara, Edapally , Kochi
Ernakulam
KERALA 
8921485541

dr.vivek.in@gmail.com 
Dr Paul J Alapatt   Aster MIMS Hospital, Calicut   Department of Neurology, Mini- Bypass Road, Govindapuram P.O, Calicut
Kozhikode
KERALA 
9447342034

pauljalapatt@gmail.com  
Dr Biman Kanti Ray  Bangur Institute of Neurosciences, Kolkata   Department of Neurosciences, Bangur Institute of Neurosciences, IPGME&R, Kolkata - 700020
Kolkata
WEST BENGAL 
9433185327

biman.kanti@rediffmail.com  
Dr Jacob Johnson  Baptist Christian Hospital, Tezpur   Baptist Christian Hospital, Mission Chariali, Tezpur-78400
Sonitpur
ASSAM 
7598626847

cooljacky44@gmail.com  
Dr S P Gorthi   Bharati Vidyapeeth DTU Medical College, Pune   Department of Neurology, Bharati Vidyapeeth (DTU) Medical College and Hospital, Pune - 411043
Pune
MAHARASHTRA 
8800233991

spgorthi@gmail.com  
Dr Ritwiz Bihari   Chandan Hospital, Lucknow   Department of Neurology, Chandan Hospital, Faizabad Road, Vijayant Khand, Gomti Nagar, Lucknow - 226010
Lucknow
UTTAR PRADESH 
7523835781

drritwizbihari@gmail.com 
Dr Jeyaraj Durai Pandian   Christian Medical College and Hospital, Ludhiana   Department of Neurology, Christian Medical College and Hospital, Ludhiana, Brown Road, Ludhiana - 141008
Ludhiana
PUNJAB 
9915784750

jeyarajpandian@hotmail.com  
Dr Sanjith Aaron  Christian Medical College, Vellore  Department of Neurological Sciences, Christian Medical College Vellore (Ranipet Campus), Kilminnal Village, Ranipet - 632 517
Vellore
TAMIL NADU 
9894022395

sanjith@cmcvellore.ac.in  
Dr Chitra P  Government Medical College, Thiruvananthapuram  Department of Neurology, Government Medical College, Medical College P.O - 695011 Thiruvananthapuram
Thiruvananthapuram
KERALA 
9495202065

drchithrap5@gmail.com 
Dr Shaji CV  Government T D Medical College, Alappuzha  Department of Neurology, Government T.D. Medical College, Vandanam
Alappuzha
KERALA 
9947487778

drshajicv@gmail.com 
Dr Sulena   Guru Gobind Singh Medical College and Hospital, Faridkot   Department of Neurology, Guru Gobind Singh Medical College and Hospital, Faridkot - 151203
Faridkot
PUNJAB 
7087907025

sulenasingh@yahoo.co.in 
Dr Sunil K Narayan  Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry   Department of Neurology, Jawaharlal Institute of Postgraduate Medical Education and Research, Dhanvanthri Nagar, Pondicherry - 605006
Pondicherry
PONDICHERRY 
9443617120

sknarayan@gmail.com 
Dr Aparna R Pai   Kasturba Hospital, Manipal   Department of Neurology, Kasturba Hospital, Manipal - 576104
Udupi
KARNATAKA 
9880182224

aparna.pai@manipal.edu  
Dr TCR Ramakrishnan  KG Hospital and Post Graduate Medical Institute & Research Centre, Coimbatore   First floor, B Block, Department of Neurology, No. 5, Government Arts College Road, Coimbatore - 641018
Coimbatore
TAMIL NADU 
9443365792

priyarams01@gmail.com 
Dr A O Saroja   KLEs Dr. Prabhakar Kore Hospital & Medical Resaerch Centre, Belagavi   Department of Neurology, KLEs Dr. Prabhakar Kore Hospital & Medical Research Centre, J.N.Medical College Campus, Nehru Nagar, Belagavi-590010
Belgaum
KARNATAKA 
9448468474

sarojaao2002@yahoo.com 
Dr P Vijaya   Lalitha Super Specialities Hospital Pvt Ltd, Guntur   Department of Neurosciences, Lalitha Super Specialities Hospital Pvt Ltd, Kothapet, Guntur - 522 001
Guntur
ANDHRA PRADESH 
9440808621

drvijayapvr@gmail.com  
Dr Radhika Lotlikar  LMFF s Deenanath Mangeshkar Hospital & Research Center  Department of Neurology, LMFF s Deenanath Mangeshkar Hospital & Research Center, Erandawane, Pune 411004
Pune
MAHARASHTRA 
9967104512

radhika.lotlikar58@gmail.com 
Dr Veena Vedartham   Manipal Hospital Bangalore  Department of Neurology, Manipal Hospital, #98 Old Airport road, Benagluru-560017
Bangalore
KARNATAKA 
9645422534

veenavedu@gmail.com 
Dr Jayanta Roy  Manipal Hospitals, Mukundapur Cluster, Kolkata   Department of Neurology, Manipal Hospitals, Mukundapur Cluster, 223 & 230, Barakhola Lane, Purba Jadavpur, Mukundapur, Kolkata -700099
Kolkata
WEST BENGAL 
9836210993

jroyneuro01@gmail.com 
Dr Girish Baburao Kulkarni  National Institute of Mental Health and Neurosciences (NIMHANS) Bangalore   Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur road Bangalore-560029
Bangalore
KARNATAKA 
9035160614

gbk5000@rediffmail.com 
Dr Darshan Doshi  PD Hinduja Hospital & MRC, Mumbai   Department of Neurology, PD Hinduja Hospital & MRC, Veer Savarkar Road, Mahim, Mumbai - 400016.
Mumbai
MAHARASHTRA 
9845633469

darshankdoshi@gmail.com 
Dr Neeraj Bhutani  Santokba Durlabhji Memorial Hospital, Jaipur   Department of Neurology, Santokba Durlabhji Memorial Hospital, Bhawani Singh Rd, Rambagh, Jaipur -302015
Jaipur
RAJASTHAN 
9828711808

drneerajbhutani@rediffmail.com 
Dr Soaham Desai  Shree Krishna Hospital, Anand  Department of Neurology, Bhaikaka University, Shree Krishna Hospital and Medical Research Centre, Gokal Nagar, Karamsad-388 325, Anand
Anand
GUJARAT 
9979937885

drsoahamdesai@yahoo.com 
Dr P N Sylaja  Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum  Room No. 3109, Stroke Office, Comprehensive Stroke Care Program, Department of Neurology, Medical College P.O. - 695011
Thiruvananthapuram
KERALA 
9446566287

sylajapn@hotmail.com 
Dr Arvind Sharma  Zydus Hospital, Ahmedabad   Department of Neurology, Zydus Hospitals & Healthcare Research Pvt. Ltd., Zydus Hospitals Road, S.G.Highway, Thaltej, Ahmedabad - 380054
Ahmadabad
GUJARAT 
9409210486

dr_arvind10@yahoo.co.in  
 
Details of Ethics Committee  
No of Ethics Committees= 28  
Name of Committee  Approval Status 
Bharati Vidyapeeth Deemed University IEC  Submittted/Under Review 
EHA Institutional Ethics committee  Submittted/Under Review 
Ethics committee of Manipal Hospitals  Submittted/Under Review 
Human Ethics Committee, GMC, Thiruvananthapuram   Submittted/Under Review 
IEC (BHR) AIIMS Bilaspur  Submittted/Under Review 
IEC AIIMS Rishikesh  Submittted/Under Review 
Institute Ethics Committee (Basic and Neurosciences Division), NIMHANS, Bangalore   Submittted/Under Review 
Institutional ethics committee (IEC), AIIMS, Bhubaneswar  Submittted/Under Review 
Institutional Ethics committee, AIMS, Kochi   Submittted/Under Review 
Institutional Ethics Committee, Chandan Hospital, Lucknow  Submittted/Under Review 
Institutional Ethics Committee, CMC and H, Ludhiana   Submittted/Under Review 
Institutional Ethics Committee, DMH and RC, Pune   Submittted/Under Review 
Institutional Ethics Committee, Govt. T.D. Medical College, Alappuzha  Submittted/Under Review 
Institutional Ethics committee, Guru Gobind Singh Medical College and Hospital, Faridkot   Approved 
Institutional Ethics committee, K G Hospital, Coimbatore   Approved 
Institutional Ethics Committee, KLEs Dr. Prabhakar Kore Hospital and Medical Research Centre, Belagavi  Submittted/Under Review 
Institutional Ethics Committee, Manipal Hospitals, Mukundapur  Submittted/Under Review 
Institutional Ethics Committee, PD Hinduja Hospital and MRC   Submittted/Under Review 
Institutional Ethics Committee, SCTIMST, Trivandrum   Submittted/Under Review 
Institutional Ethics Committee, Shree Krishna Hospital and Medical Research Centre, Anand  Submittted/Under Review 
Institutional Review Board (IRB), CMC Vellore  Submittted/Under Review 
IPGME and R Research Oversight Committee  Approved 
JIPMER Institute Ethics Committee (Human-Interventional)   Submittted/Under Review 
Kasturba Medical College and Kasturba Hospital Institutional Ethics Committee (KMC and KH IEC)   Submittted/Under Review 
Lalitha Super Specialities Hospital Ethics Committee  Approved 
Malabar Institute of Medical Sciences Ethics Committee   Submittted/Under Review 
SDMH Ethics Committee  Submittted/Under Review 
Zydus Hospital Ethics Committee  Submittted/Under Review 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: I639||Cerebral infarction, unspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Intravenous tenecteplase  Low-dose intravenous tenecteplase (0.18 mg/kg body weight) 
Intervention  Intravenous tenecteplase  Standard-dose intravenous tenecteplase (0.25 mg/kg body weight) 
Comparator Agent  No intravenous tenecteplase  Only participants on Direct Oral Anticoagulants (DOACs) or those scheduled for emergency endovascular thrombectomy (EVT) are eligible for no intravenous tenecteplase. Participants who are on DOACs within the last 48 hours or those planned for emergency EVT will be randomized to receive either Standard-dose intravenous tenecteplase (0.25 mg/kg body weight) (OR) Low-dose intravenous tenecteplase (0.18 mg/kg body weight) (OR) No intravenous tenecteplase 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  99.00 Year(s)
Gender  Both 
Details  1. Age greater than or equal to 18 years
2. Clinical diagnosis of stroke
3. All patients with disabling AIS presenting within 4.5 hours of symptom onset or last known well who may benefit from intravenous thrombolysis (IVT) with tenecteplase. Patients potentially eligible for IVT with conditions described as relative contraindications in national guidelines where physician discretion is recommended are eligible. Patients who received a DOAC, and those planned for EVT are eligible.
4. Consent process completed as per national laws and regulations and the applicable ethics committee requirements. 
 
ExclusionCriteria 
Details  1. Any absolute contraindication for IV thrombolysis per current national guidelines. Examples include those who have active bleeding, recent (less than 7 days) intracranial surgery, head trauma, intracranial or subarachnoid hemorrhage, or have a bleeding diathesis.
2. Minor stroke patients with non-disabling symptoms. 
 
Method of Generating Random Sequence   Permuted block randomization, variable 
Method of Concealment   Centralized 
Blinding/Masking   Outcome Assessor Blinded 
Primary Outcome  
Outcome  TimePoints 
modified Rankin scale (mRS) scores  Day 90 
 
Secondary Outcome  
Outcome  TimePoints 
Proportion of participants with mRS score of 0-1
 
Day 90 
Proportion of participants with mRS score of 0-2
 
Day 90 
Health-related quality of life, as measured by the EQ-5D-5L  Day 90 
Ordinal shift of 7 levels of mRS at 90 days
 
Day 90 
Ambulatory status at discharge
 
NIL 
Place of residence  Day 90 
Imaging assessments (e.g., infarct and edema volumes)  NIL 
Proportion of participant achieving revised arterial occlusive lesion [rAOL] score of 2b-3 at first angiographic images (when treated with EVT)
 
NIL 
Proportion of participants achieving first pass reperfusion expanded treatment in cerebral ischemia (eTICI) 2c or higher (when treated with EVT)
 
NIL 
Summative total length of hospital stay in the first 90-days after stroke onset  Day 90 
Mortality  Day 90 
Symptomatic intracranial hemorrhage, Large parenchymal hemorrhage (PH-2)  NIL 
SAEs  Within 4 days 
 
Target Sample Size   Total Sample Size="4000"
Sample Size from India="500" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   01/03/2026 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  26/09/2024 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="5"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Open to Recruitment 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - YES
  1. What data in particular will be shared?
    Response - All of the individual participant data collected during the trial, after de-identification.

  2. What additional supporting information will be shared?
    Response -  Study Protocol
    Response -  Statistical Analysis Plan
    Response - Informed Consent Form

  3. Who will be able to view these files?
    Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.

  4. For what types of analyses will this data be available?
    Response - To achieve aims in the approved proposal.

  5. By what mechanism will data be made available?
    Response - Proposals should be directed to [bkmmenon@ucalgary.ca].

  6. For how long will this data be available start date provided 01-11-2025 and end date provided 31-10-2035?
    Response - Beginning 3 months and ending 5 years following article publication.

  7. Any URL or additional information regarding plan/policy for sharing IPD? 
    Additional Information - NIL
Brief Summary  
This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design. Up to 4,000 patients with presumed acute ischemic stroke (AIS) will be followed for 90 days (or until death, if prior to 90 days). The end of the trial is defined as the date that all participants have completed their Day 90 assessment.

This domain aim is to efficiently, reliably, and simultaneously, determine the comparative effectiveness of intravenous thrombolysis (IVT) using standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) in all patients who present to hospital with acute ischemic stroke and are considered for intravenous thrombolysis. In addition, this domain also seeks to study standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) vs. no TNK upfront with rescue IA TNK if necessary (in those eligible for emergency EVT) and no TNK upfront in those who have taken DOACs during the preceding 24 hours. This domain therefore seeks to generate more robust randomized evidence to guide clinicians in their decisions over the balance of risks and treatment with intravenous thrombolysis with tenecteplase wherever such evidence is currently insufficient.

This domain will currently evaluate four research questions about the use of IVT with tenecteplase:

1. In patients with recent (24 hours) intake of a standard-dose direct oral anticoagulant (DOAC), how should IVT be used? - Use standard-dose (0.25 mg/kg body weight) or low-dose tenecteplase (0.18 mg/kg) or not at all.
2. In patients planned to be treated with endovascular thrombectomy, how should tenecteplase be used? -Treat with IV tenecteplase (standard- or low-dose) or not at all.
3. In any patient receiving IVT, what is the optimal dose of tenecteplase? - use standard-dose (0.25 mg/kg body weight) or low-dose tenecteplase (0.18 mg/kg).
4. To what extent is the treatment effect of standard- vs. low-dose tenecteplase modified by key patient characteristics, such as diabetes, prior antiplatelet therapy, renal failure, or frailty, old age, or having a heavy burden of cerebral small vessel disease on brain imaging?
 
Close